1
|
Tong X, Raffaele J, Feller K, Dornadula G, Devlin J, Boyd D, Loughney JW, Shanter J, Rustandi RR. Correlating Stability-Indicating Biochemical and Biophysical Characteristics with In Vitro Cell Potency in mRNA LNP Vaccine. Vaccines (Basel) 2024; 12:169. [PMID: 38400152 PMCID: PMC10893231 DOI: 10.3390/vaccines12020169] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/08/2024] [Revised: 02/02/2024] [Accepted: 02/05/2024] [Indexed: 02/25/2024] Open
Abstract
The development of mRNA vaccines has increased rapidly since the COVID-19 pandemic. As one of the critical attributes, understanding mRNA lipid nanoparticle (LNP) stability is critical in the vaccine product development. However, the correlation between LNPs' physiochemical characteristics and their potency still remains unclear. The lack of regulatory guidance on the specifications for mRNA LNPs is also partially due to this underexplored relationship. In this study, we performed a three-month stability study of heat-stressed mRNA LNP samples. The mRNA LNP samples were analyzed for their mRNA degradation, LNP particle sizes, and mRNA encapsulation efficiency. In vitro cell potency was also evaluated and correlated with these above-mentioned physiochemical characterizations. The mRNA degradation-cell potency correlation data showed two distinct regions, indicating a critical cut-off size limit for mRNA degradation. The same temperature dependence was also observed in the LNP size-cell potency correlation.
Collapse
Affiliation(s)
- Xin Tong
- Analytical Research & Development, Merck & Co., Inc., Rahway, NJ 07065, USA (K.F.); (G.D.); (J.W.L.); (R.R.R.)
| | - Jessica Raffaele
- Analytical Research & Development, Merck & Co., Inc., Rahway, NJ 07065, USA (K.F.); (G.D.); (J.W.L.); (R.R.R.)
| | - Katrina Feller
- Analytical Research & Development, Merck & Co., Inc., Rahway, NJ 07065, USA (K.F.); (G.D.); (J.W.L.); (R.R.R.)
| | - Geethanjali Dornadula
- Analytical Research & Development, Merck & Co., Inc., Rahway, NJ 07065, USA (K.F.); (G.D.); (J.W.L.); (R.R.R.)
| | - James Devlin
- Analytical Research & Development, Merck & Co., Inc., Rahway, NJ 07065, USA (K.F.); (G.D.); (J.W.L.); (R.R.R.)
| | - David Boyd
- Process Research & Development, Merck & Co., Inc., Rahway, NJ 07065, USA; (D.B.); (J.S.)
| | - John W. Loughney
- Analytical Research & Development, Merck & Co., Inc., Rahway, NJ 07065, USA (K.F.); (G.D.); (J.W.L.); (R.R.R.)
| | - Jon Shanter
- Process Research & Development, Merck & Co., Inc., Rahway, NJ 07065, USA; (D.B.); (J.S.)
| | - Richard R. Rustandi
- Analytical Research & Development, Merck & Co., Inc., Rahway, NJ 07065, USA (K.F.); (G.D.); (J.W.L.); (R.R.R.)
| |
Collapse
|
2
|
Trucillo P. Biomaterials for Drug Delivery and Human Applications. MATERIALS (BASEL, SWITZERLAND) 2024; 17:456. [PMID: 38255624 PMCID: PMC10817481 DOI: 10.3390/ma17020456] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/26/2023] [Revised: 01/12/2024] [Accepted: 01/16/2024] [Indexed: 01/24/2024]
Abstract
Biomaterials embody a groundbreaking paradigm shift in the field of drug delivery and human applications. Their versatility and adaptability have not only enriched therapeutic outcomes but also significantly reduced the burden of adverse effects. This work serves as a comprehensive overview of biomaterials, with a particular emphasis on their pivotal role in drug delivery, classifying them in terms of their biobased, biodegradable, and biocompatible nature, and highlighting their characteristics and advantages. The examination also delves into the extensive array of applications for biomaterials in drug delivery, encompassing diverse medical fields such as cancer therapy, cardiovascular diseases, neurological disorders, and vaccination. This work also explores the actual challenges within this domain, including potential toxicity and the complexity of manufacturing processes. These challenges emphasize the necessity for thorough research and the continuous development of regulatory frameworks. The second aim of this review is to navigate through the compelling terrain of recent advances and prospects in biomaterials, envisioning a healthcare landscape where they empower precise, targeted, and personalized drug delivery. The potential for biomaterials to transform healthcare is staggering, as they promise treatments tailored to individual patient needs, offering hope for improved therapeutic efficacy, fewer side effects, and a brighter future for medical practice.
Collapse
Affiliation(s)
- Paolo Trucillo
- Department of Chemical, Materials and Industrial Production Engineering, University of Naples Federico II, Piazzale V. Tecchio, 80, 80125 Naples, Italy
| |
Collapse
|
3
|
Rodriguez-Loya J, Lerma M, Gardea-Torresdey JL. Dynamic Light Scattering and Its Application to Control Nanoparticle Aggregation in Colloidal Systems: A Review. MICROMACHINES 2023; 15:24. [PMID: 38258143 PMCID: PMC10819909 DOI: 10.3390/mi15010024] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/26/2023] [Revised: 11/21/2023] [Accepted: 11/29/2023] [Indexed: 01/24/2024]
Abstract
Colloidal systems and their control play an essential role in daily human activities, but several drawbacks lead to an avoidance of their extensive application in some more productive areas. Some roadblocks are a lack of knowledge regarding how to influence and address colloidal forces, as well as a lack of practical devices to understand these systems. This review focuses on applying dynamic light scattering (DLS) as a powerful tool for monitoring and characterizing nanoparticle aggregation dynamics. We started by outlining the core ideas behind DLS and how it may be used to examine colloidal particle size distribution and aggregation dynamics; then, in the last section, we included the options to control aggregation in the chemically processed toner. In addition, we pinpointed knowledge gaps and difficulties that obstruct the use of DLS in real-world situations. Although widely used, DLS has limits when dealing with complicated systems, including combinations of nanoparticles, high concentrations, and non-spherical particles. We discussed these issues and offered possible solutions and the incorporation of supplementary characterization approaches. Finally, we emphasized how critical it is to close the gap between fundamental studies of nanoparticle aggregation and their translation into real-world applications, recognizing challenges in colloidal science.
Collapse
Affiliation(s)
- Jesus Rodriguez-Loya
- Environmental Science and Engineering Ph. D. Program, University of Texas at El Paso, El Paso, TX 79968, USA; (J.R.-L.); (M.L.)
| | - Maricarmen Lerma
- Environmental Science and Engineering Ph. D. Program, University of Texas at El Paso, El Paso, TX 79968, USA; (J.R.-L.); (M.L.)
| | - Jorge L. Gardea-Torresdey
- Environmental Science and Engineering Ph. D. Program, University of Texas at El Paso, El Paso, TX 79968, USA; (J.R.-L.); (M.L.)
- Department of Chemistry and Biochemistry, University of Texas at El Paso, El Paso, TX 79968, USA
| |
Collapse
|
4
|
Shim K, Jo H, Jeoung D. Cancer/Testis Antigens as Targets for RNA-Based Anticancer Therapy. Int J Mol Sci 2023; 24:14679. [PMID: 37834126 PMCID: PMC10572814 DOI: 10.3390/ijms241914679] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2023] [Revised: 09/25/2023] [Accepted: 09/27/2023] [Indexed: 10/15/2023] Open
Abstract
In the last few decades, RNA-based drugs have emerged as a promising candidate in the treatment of various diseases. The introduction of messenger RNA (mRNA) as a vaccine or therapeutic agent enables the production of almost any functional protein/peptide. The key to applying RNA therapy in clinical trials is developing safe and effective delivery systems. Exosomes and lipid nanoparticles (LNPs) have been exploited as promising vehicles for drug delivery. This review discusses the feasibility of exosomes and LNPs as vehicles for mRNA delivery. Cancer/testis antigens (CTAs) show restricted expression in normal tissues and widespread expression in cancer tissues. Many of these CTAs show expression in the sera of patients with cancers. These characteristics of CTAs make them excellent targets for cancer immunotherapy. This review summarizes the roles of CTAs in various life processes and current studies on mRNAs encoding CTAs. Clinical studies present the beneficial effects of mRNAs encoding CTAs in patients with cancers. This review highlight clinical studies employing mRNA-LNPs encoding CTAs.
Collapse
Affiliation(s)
| | | | - Dooil Jeoung
- Department of Biochemistry, College of Natural Sciences, Kangwon National University, Chuncheon 24341, Republic of Korea; (K.S.); (H.J.)
| |
Collapse
|